Since PD-1 is expressed not only on immune cells but also on tumor cells, the superior clinical activity and safety profile of anti-PD-1 compared with anti-CTLA-4 therapy may be due to the additional effects of anti-PD-1 on targeting tumor-intrinsic signaling (7, 9, 28). This evidence concerns the gene CTLA4 and neoplasm.